ArticleJournal of cardiothoracic surgery2026
Rosuvastatin calcium administration and its impact on myocardial microcirculation and postoperative recovery in patients undergoing coronary artery bypass grafting.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary artery bypass grafting (CABG) is a common intervention for coronary artery disease, but postoperative myocardial microcirculation and recovery remain challenging. This study aimed to evaluate the effects of rosuvastatin calcium on myocardial microcirculation and postoperative outcomes in CABG patients.
methodsThis retrospective cohort study included 216 patients who underwent CABG between February 2020 and February 2024. Participants were divided into a conventional treatment group (n = 111) and a rosuvastatin group (n = 105) receiving additional rosuvastatin calcium (10 mg/day) from 7 days pre-surgery to 28 days post-surgery. Cardiac echocardiography, blood tests (inflammatory markers, lipids, and cardiac enzymes), and New York Heart Association (NYHA) functional classification were assessed preoperatively and 8 weeks postoperatively. Postoperative complications and mortality were monitored during a one-year follow-up.
resultsThe rosuvastatin group showed significantly improved left ventricular remodeling, with reduced left ventricular end-diastolic diameter (LVEDD, P = 0.022), Left Ventricular Septal Thickness (LVST, P = 0.048), and Left Ventricular Posterior Wall Thickness (LVPWT, P = 0.019). Enhanced systolic function was evidenced by higher LVEF (P < 0.001) and Left Ventricular Fractional Shortening (LVFS, P < 0.001). Myocardial microcirculation parameters including Left Acceleration Time (AT), Pulsatility Index (PI), and Aortic Pre-Ejection Period (APT) also improved (all P < 0.05). Additionally, the rosuvastatin group had lower postoperative creatine kinase MB isoenzyme (CK-MB, P = 0.012), higher High-Density Lipoprotein Cholesterol (HDL-C, P = 0.003), and reduced incidence of atrial fibrillation (P = 0.007) and all-cause mortality (P = 0.026).
conclusionRosuvastatin calcium administration significantly improves myocardial microcirculation, cardiac function, and postoperative recovery in CABG patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.